Chimeric IL-10 proteins and uses thereof
AssigneeThe Beth Israel Hospital Association
InventorsTerry B. Strom, Xin Xiao Zheng, Alan Steele
Life of this patent
Estimating the term…
Abstract
Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
Claims18
A method for treating, or inhibiting the onset of, septic shock, Type I diabetes, or multiple myeloma in a patient, the method comprising administering to the patient a therapeutically effective amount of a chimeric protein comprising interleukin-10 (IL-10) and a polypeptide that increases the circulating half-life of the IL-10-containing chimera relative to that of IL-10 alone.
A chimeric protein comprising interleukin-10 (IL-10) and a polypeptide that increases the circulating half-life of the IL-10-containing chimera relative to that of IL-10 alone.
Dependencies are inferred from the claim text.